Literature DB >> 16378247

Isoprenylated proteins.

S J McTaggart1.   

Abstract

Isoprenoids are synthesized in all living organisms and are incorporated into diverse classes of end-products that participate in a multitude of cellular processes relating to cell growth, differentiation, cytoskeletal function and vesicle trafficking. In humans, the non-sterol isoprenoids, farnesyl pyrophosphate and geranylgeranyl-pyrophosphate, are synthesized via the mevalonate pathway and are covalently added to members of the small G protein superfamily. Isoprenylated proteins have key roles in membrane attachment and protein functionality, have been shown to have a central role in some cancers and are likely also to be involved in the pathogenesis and progression of atherosclerosis and Alzheimer disease. This review details current knowledge on the biosynthesis of isoprenoids, their incorporation into proteins by the process known as prenylation and the complex regulatory network that controls these proteins. An improved understanding of these processes is likely to lead to the development of novel therapies that will have important implications for human health and disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16378247     DOI: 10.1007/s00018-005-5298-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  115 in total

Review 1.  Protein farnesylation and disease.

Authors:  Giuseppe Novelli; Maria Rosaria D'Apice
Journal:  J Inherit Metab Dis       Date:  2012-02-04       Impact factor: 4.982

2.  Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y₁₂ receptor-mediated platelet aggregation.

Authors:  Carl Högberg; Olof Gidlöf; Francesca Deflorian; Kenneth A Jacobson; Aliaa Abdelrahman; Christa E Müller; Björn Olde; David Erlinge
Journal:  Thromb Haemost       Date:  2012-05-25       Impact factor: 5.249

3.  Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer.

Authors:  Wei Yang; Quan Cai; Vivian W Y Lui; Patrick A Everley; Jayoung Kim; Neil Bhola; Kelly M Quesnelle; Bruce R Zetter; Hanno Steen; Michael R Freeman; Jennifer R Grandis
Journal:  J Proteome Res       Date:  2010-06-04       Impact factor: 4.466

4.  Protein isoprenylation regulates osteogenic differentiation of mesenchymal stem cells: effect of alendronate, and farnesyl and geranylgeranyl transferase inhibitors.

Authors:  G Duque; C Vidal; D Rivas
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

5.  Simvastatin induces a central hypotensive effect via Ras-mediated signalling to cause eNOS up-regulation.

Authors:  Wen-Han Cheng; Wen-Yu Ho; Chien-Feng Chang; Pei-Jung Lu; Pei-Wen Cheng; Tung-Chen Yeh; Ling-Zong Hong; Gwo-Ching Sun; Michael Hsiao; Ching-Jiunn Tseng
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

Review 6.  Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway.

Authors:  Annalisa Marcuzzi; Elisa Piscianz; Claudia Loganes; Liza Vecchi Brumatti; Alessandra Knowles; Sabrine Bilel; Alberto Tommasini; Roberta Bortul; Marina Zweyer
Journal:  Int J Mol Sci       Date:  2015-12-30       Impact factor: 5.923

7.  Simvastatin treatment enhances NMDAR-mediated synaptic transmission by upregulating the surface distribution of the GluN2B subunit.

Authors:  Marc-Alexander L T Parent; David A Hottman; Shaowu Cheng; Wei Zhang; Lori L McMahon; Li-Lian Yuan; Ling Li
Journal:  Cell Mol Neurobiol       Date:  2014-04-01       Impact factor: 5.046

Review 8.  Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.

Authors:  W Gibson Wood; Ling Li; Walter E Müller; Gunter P Eckert
Journal:  J Neurochem       Date:  2014-01-02       Impact factor: 5.372

Review 9.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

10.  Detection of a novel missense mutation in the mevalonate kinase gene in one Chinese family with DSAP.

Authors:  Wen-Sheng Lu; Xiao-Dong Zheng; Xiu-Hua Yao; Lan-Fang Zhang; Bai Hu; Yao-Juan Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.